Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30736687 | 0.98 | CYP4F2 (0.41) | CYP4F2CYP4A11DGAT1CYP2C19CTSK | |
| SCHEMBL6268101 | 0.96 | CYP4F2 (0.42) | CYP4F2CYP4A11DGAT1CTSKNR1H2 | |
| SCHEMBL10004678 | 0.92 | CYP4F2 (0.48) | CYP4F2CYP4A11DGAT1CTSKNR1H2 | |
| SCHEMBL15268879 | 0.82 | CYP4F2 (0.38) | CYP4F2CYP4A11DGAT1CYP2C19CTSK | |
| SCHEMBL22071050 | 0.82 | CYP4F2 (0.58) | CYP4F2CYP4A11DGAT1CTSKTDP1 | |
| SCHEMBL3295173 | 0.81 | CYP4F2 (0.38) | CYP4F2CYP4A11DGAT1CYP2C19CTSK | |
| SCHEMBL22071018 | 0.80 | CYP4F2 (0.66) | CYP4F2CYP4A11DGAT1CTSKTDP1 | |
| SCHEMBL16660833 | 0.79 | DGAT1 (0.46) | CYP4F2CYP4A11DGAT1CYP2C19CTSK | |
| SCHEMBL9720226 | 0.79 | CYP4F2 (0.64) | CYP4F2CYP4A11CYP2C19CTSKTDP1 | |
| SCHEMBL1764579 | 0.79 | CYP4F2 (0.63) | CYP4F2CYP4A11CYP2C19NR1H2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| CN-111454188-A | Cyclopropylamines as L SD1inhibitors | 因赛特公司 | 2020-07-28 | — | — | CN | disclosed |
| US-10717737-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717737-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-07-21 | — | — | US | disclosed |
| EP-3626713-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Incyte Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS (FR) | 2014-06-12 | — | — | US | disclosed |
| US-8703747-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS | 2011-05-26 | — | — | US | disclosed |
| EP-0767794-B1 | PHOSPHINIC ACID DERIVATIVES | SCHERING CORP (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5476847-A | Treating cardiovascular, gastrointestinal, urogenital disorders | SCHERING CORPORATION (US) | 1995-12-19 | — | — | US | disclosed |
| US-5407960-A | For cardiovascualr disorders, pain | SCHERING CORPORATION (US) | 1995-04-18 | — | — | US | disclosed |
| WO-1991009840-A1 | MERCAPTOCYCLOACYL AMINOACID ENDOPEPTIDASE INHIBITORS | SCHERING CORPORATION (US) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | CYP4F2 1640/4885CYP4A11 1230/4885DGAT1 1497/4885 |
| US-10717737-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | CYP4F2 1640/4885CYP4A11 1230/4885DGAT1 1497/4885 |
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | CYP4F2 2280/4885CYP4A11 1103/4885DGAT1 4098/4885 |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | CYP4F2 1640/4885CYP4A11 1230/4885DGAT1 1497/4885 |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | CYP4F2 1640/4885CYP4A11 1230/4885DGAT1 1497/4885 |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | CYP4F2 2255/4885CYP4A11 1224/4885DGAT1 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.